Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.65 |
| ▸ | PPARG | P37231 | 7/20 | 0.65 |
| ▸ | PPARD | Q03181 | 7/20 | 0.65 |
| ▸ | PPARA | Q07869 | 7/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | FABP4 | P15090 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TLR2 | O60603 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Behenic Acid SCHEMBL28872369 | 1.00 | GPR84 (0.65) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL28341855 | 0.87 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL25293218 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL25287435 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| Lignoceric Acid SCHEMBL23751106 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL25291604 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| Myristic Acid SCHEMBL25290278 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dotriacontanoic Acid SCHEMBL25298401 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL25291231 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL25295592 | 0.81 | GPR84 (1.00) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127213-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF | PARK, OK NAM (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230103514-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-04-06 | — | — | US | disclosed |
| US-20230100173-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-03-30 | — | — | US | disclosed |
| EP-4117699-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| EP-4117698-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| EP-4117700-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021182873-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF. | MEDIHELPLINE CO., LTD. (KR) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021182865-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF. | MEDIHELPLINE CO., LTD. (KR) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021182864-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF. | MEDIHELPLINE CO., LTD (KR) | 2021-09-16 | — | — | WO | disclosed |
| US-20200078272-A1 | METHOD FOR PRODUCING CERAMIDE MICROPARTICLE DISPERSION | KAO CORPORATION (JP) | 2020-03-12 | — | — | US | disclosed |
| WO-2006090939-A1 | COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING | BIOLAND LTD. (KR) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006016728-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS | HELIXIR CO., LTD. (KR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1551433-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | Pangenomics Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004017982-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | PANGENOMICS CO., LTD (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040037909-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | VIROMED CO., LTD. (KR) | 2004-02-26 | — | — | US | disclosed |
| EP-0950407-B1 | The use of a GP IIb/IIIa antagonist for the manufacture of a medicament suitable for transdermal application by iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6322550-B2 | Method for transdermal administration of GP IIb/IIIa antagonist | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-11-27 | — | — | US | disclosed |
| US-20010018568-A1 | METHOD FOR TRANSDERMAL ADMINISTRATION OF GP IIB/IIIA ANTAGONIST | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-08-30 | — | — | US | disclosed |
| EP-0950407-A1 | Method for transdermal administration of GP IIb/IIIa antagonist | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078272-A1 | METHOD FOR PRODUCING CERAMIDE MICROPARTICLE DISPERSION | SGMS1, CERS2, SGMS2 | GPR84 2795/4885PPARG 3319/4885PPARD 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.